 Regenxbio Inc NASDAQ: RGNX announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic retinopathy DR without center-involved diabetic macular edema CI-DME. The data were presented at the American Society of Retina Specialists Annual Meeting. 